In this study, besides tumor-infiltrating CCR6+ Treg-cells we have confirmed the direct contribution of CCR6 expressed by CMT93 CRC cells to the CRC growth and development in CCR6−/− mice, the clinical application of targeting the CCR6-CCL20 chemokine axis may harbor therapeutic potential for the treatment of patients with CRC. This evidence concerns the gene CCR6 and colorectal carcinoma.